Typical Antibiotic for Pneumonia in Long-Term Nursing/Skilled Nursing Facilities
For nursing home residents with pneumonia who are not at high risk of mortality and have no risk factors for MRSA, treat with a respiratory fluoroquinolone (levofloxacin 750 mg IV daily) OR a beta-lactam (piperacillin-tazobactam 4.5 g IV q6h, cefepime 2 g IV q8h, imipenem 500 mg IV q6h, or meropenem 1 g IV q8h) as monotherapy.
Risk Stratification Determines Antibiotic Choice
The key to selecting antibiotics for nursing home-acquired pneumonia is determining the resident's risk profile, which directly impacts mortality and morbidity outcomes.
Low-Risk Residents (No MRSA Risk Factors, Not High Mortality Risk)
Monotherapy options 1:
- Levofloxacin 750 mg IV daily (preferred for convenience and broad coverage)
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime 2 g IV q8h
- Imipenem 500 mg IV q6h
- Meropenem 1 g IV q8h
These residents can be treated with single-agent therapy targeting typical pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and methicillin-sensitive Staphylococcus aureus (MSSA) 2, 3.
High-Risk Residents Requiring MRSA Coverage
Add MRSA coverage if ANY of the following apply 1:
- IV antibiotic use within the prior 90 days
- Hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant
- MRSA prevalence unknown in the facility
- High risk of mortality (requiring ventilatory support or septic shock)
For these residents, use dual therapy 1:
- One of the above beta-lactams or fluoroquinolones PLUS
- Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL) OR
- Linezolid 600 mg IV q12h
Very High-Risk or Recent Antibiotic Exposure
For residents with high mortality risk OR IV antibiotics in the prior 90 days, use combination therapy with TWO agents from different classes (avoid two beta-lactams) 1:
Choose two from:
- Beta-lactam (piperacillin-tazobactam, cefepime, or carbapenem)
- Fluoroquinolone (levofloxacin 750 mg or ciprofloxacin 400 mg IV q8h)
- Aminoglycoside (gentamicin 5-7 mg/kg IV daily, tobramycin 5-7 mg/kg IV daily, or amikacin 15-20 mg/kg IV daily)
PLUS vancomycin or linezolid for MRSA coverage
Critical Clinical Considerations
Important Caveats
Recent antibiotic exposure is a game-changer: If the resident received IV antibiotics within 90 days, this automatically escalates them to high-risk status requiring broader coverage 1. This reflects the reality that prior antibiotic exposure selects for resistant organisms.
Know your facility's antibiogram: The 20% MRSA threshold is a guideline, but individual facilities should adjust based on local resistance patterns 1. If your facility consistently sees high MRSA rates, empiric coverage becomes more critical for reducing mortality.
Aspiration risk is common but doesn't change initial antibiotics: While aspiration pneumonia is prevalent in nursing home residents 2, 4, the recommended regimens already provide adequate anaerobic coverage (particularly piperacillin-tazobactam and carbapenems).
Common Pitfalls to Avoid
Don't automatically assume all nursing home pneumonia requires broad-spectrum antibiotics: The evidence shows that Streptococcus pneumoniae remains the most common pathogen, even in nursing homes 2, 3, 5. Overuse of broad-spectrum antibiotics drives resistance without improving outcomes in low-risk residents.
Don't use monotherapy with a macrolide alone: While older guidelines suggested this, current evidence demonstrates inadequate coverage and poor outcomes 3. Macrolides should only be used in combination with a beta-lactam if fluoroquinolones are contraindicated.
Beware fluoroquinolone adverse effects in the elderly: Despite their efficacy, fluoroquinolones carry risks of tendon rupture, QT prolongation, and delirium in older adults 6. However, for residents without these specific contraindications, the mortality benefit outweighs these risks.
Treatment Duration and Monitoring
Duration: 5-8 days is typically sufficient for most cases 7, 3. Extend only if clinical resolution is absent or Pseudomonas aeruginosa is identified.
Switch to oral therapy: Transition from IV to oral when the resident is hemodynamically stable, clinically improving, and able to take oral medications 8. This often occurs within 2-3 days.
Antibiotic timeout: Reassess at 48-72 hours with culture results and clinical response 2. De-escalate therapy based on identified pathogens and susceptibilities to minimize resistance and adverse effects.
Special Population: Advanced Dementia
For residents with advanced dementia in terminal stages, consider whether antibiotics align with goals of care 5, 4. Comfort-focused care may be more appropriate than aggressive treatment, requiring advance care planning discussions with families.